Highlights H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:06:54 20/05/2026 pm IST			5-day change	1st Jan Change
41.22 ^DKK	+2.64%		-0.72%	-4.82%

18/05	Lundbeck's Asedebart Secures Orphan Drug Designation in Japan	MT
18/05	Lundbeck granted Orphan Drug Designation in Japan for asedebart	FW

Highlights

18/05	Lundbeck's Asedebart Secures Orphan Drug Designation in Japan	MT
13/05	H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation
12/05	H. Lundbeck A/S Raises Earning Guidance for Full Year of 2026	CI
12/05	H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
19/04	H. Lundbeck A/S Presents New Data At AAN2026 Highlighting Real-World Changes in Migraine-Related Cognitive Symptoms After Starting VYEPTI® (Eptinezumab)	CI
23/03	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
20/03	H Lundbeck: Markets need more proof of growth promise
18/03	H. Lundbeck A/S Approves Dividend for the Accounting Year 2025	CI
16/03	H. Lundbeck A/S Advances Parkinson's Research With New Phase 1b Data On Lu AF28996 And Presents Updates On Multiple System Atrophy Programs	CI
09/03	H. Lundbeck A/S Announces Last Patient Randomized in Phase 3 Mascot Trial	CI
12/02	H. Lundbeck A/S Announces Positive Phase IIb Top-Line Results with Bocunebart (Lu AG09222; Anti-PACAP mAb) in Migraine Prevention	CI
06/02	H Lundbeck: Weak 2026 outlook a turn-off for investors
04/02	H. Lundbeck A/S Proposes Dividend for 2025	CI
04/02	H. Lundbeck A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
30/01	H. Lundbeck A/S Announces Six-Month Data from the 12-Month, Real-World Infuse Study	CI
06/12	H. Lundbeck A/S Announces Positive Phase 2 Long-Term Data for Bexicaserin in Rare Childhood-Onet Epilepsies, at American Epilepsy Society Annual Meeting	CI
02/12	H. Lundbeck A/S Presents Comprehensive New Bexicaserin Dataset Epilepsies	CI
26/11	Lundbeck Will Not Raise Its Bid for Avadel	FW
19/11	Alkermes Raises Offer for Avadel to $22.50 Per Share	FW
19/11	H. Lundbeck A/S (CPSE:HLUN B) cancelled the acquisition of Avadel Pharmaceuticals plc.	CI
17/11	Avadel Pharmaceuticals Board Deems Lundbeck's Takeover Proposal Superior	FW
14/11	H Lundbeck lifts guidance again as migraine and depression drugs drive growth
14/11	H. Lundbeck A/S (CPSE:HLUN B) submitted a non binding proposal to acquire Avadel Pharmaceuticals plc for $2.1 billion.	CI
14/11	Lundbeck Makes Bid for Irish Firm Avadel Pharmaceuticals	FW
14/11	Lundbeck's New Drug Application for Migraine Preventive Drug Accepted by Japanese Ministry	MT